ArticleActa pharmaceutica Sinica. B2020
Icariside Ⅱ, a main compound in Epimedii Folium, induces idiosyncratic hepatotoxicity by enhancing NLRP3 inflammasome activation.
Article in Acta pharmaceutica Sinica. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 99 citations in OpenAlex.
- Monosodium urate crystals induce lytic macrophage death partially dependent on both pyroptosis and necroptosis.Clinical rheumatology · 2026Article
- A Multimodal deep learning method for predicting drug-induced liver injury using structural and sequential molecular representations.Journal of computer-aided molecular design · 2026Article
- Review
- Review
- Carnosic Acid Directly Targets STING C-Terminal Tail to Improve STING-Mediated Inflammatory Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exosomes derived from liver failure patients' plasma stimulated mesenchymal stem cells alleviate acute liver failure.Stem cell research & therapy · 2025Article
- Article
- Susceptibility Factor TNF-α Synergizes withJournal of inflammation research · 2025Article
- Sophora tonkinensis enhances activation of cGAS-STING pathway and restrains HBV replication.Frontiers in pharmacology · 2025Article
- Extinguishing the flames of inflammation: retardant effect of chlorquinaldol on NLRP3-driven diseases.Molecular medicine (Cambridge, Mass.) · 2024Article
- Pentagalloylglucose alleviates acetaminophen-induced acute liver injury by modulating inflammation via cGAS-STING pathway.Molecular medicine (Cambridge, Mass.) · 2024Article
- Total tanshinones ameliorates cGAS-STING-mediated inflammatory and autoimmune diseases by affecting STING-IRF3 binding.Chinese medicine · 2024Article
- Homotherapy for heteropathy: therapeutic effect of Butein in NLRP3-driven diseases.Cell communication and signaling : CCS · 2024Article
- Evaluation on the Potential for Hepatotoxic Components from Herba Epimedii to Induce Apoptosis in HepG2 Cells and the Analysis of the Influence of Metabolism in Liver Microsomes.Molecules (Basel, Switzerland) · 2024Article
- Growing attention on the toxicity of Chinese herbal medicine: a bibliometric analysis from 2013 to 2022.Frontiers in pharmacology · 2024Article
- Potential Impact of Bioactive Compounds as NLRP3 Inflammasome Inhibitors: An Update.Current pharmaceutical biotechnology · 2024Review
- Anti-inflammatory and uric acid lowering effects of Euodiae fructus on hyperuricemia and gout mice.Frontiers in pharmacology · 2024Article
- Comprehensive review of the traditional uses and the potential benefits of epimedium folium.Frontiers in pharmacology · 2024Review
- Baohuoside I inhibits FXR signaling pathway to interfere with bile acid homeostasis via targeting ER α degradation.Cell biology and toxicology · 2023Article
- Tanshinone I specifically suppresses NLRP3 inflammasome activation by disrupting the association of NLRP3 and ASC.Molecular medicine (Cambridge, Mass.) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Idiosyncratic drug-induced liver injury (IDILI) is an infrequent but potentially serious disease that develops the main reason for post-marketing safety warnings and withdrawals of drugs. Epimedii Folium (EF), the widely used herbal medicine, has shown to cause idiosyncratic liver injury, but the underlying mechanisms are poorly understood. Increasing evidence has indicated that most cases of IDILI are immune mediated. Here, we report that icariside Ⅱ (ICS Ⅱ), the major active and metabolic constituent of EF, causes idiosyncratic liver injury by promoting NLRP3 inflammasome activation. ICS Ⅱ exacerbates NLRP3 inflammasome activation triggered by adenosine triphosphate (ATP) and nigericin, but not silicon dioxide (SiO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.